Senior Research Fellow
Alex graduated with a Bsc (Hons I) in Molecular and Cellular Biology from UNSW in 1995. After obtaining his PhD in 2003 he undertook postdoctoral training with Nobel laureate J. Michael Bishop at the University of California, San Francisco, supported by a CJ Martin Travelling Fellowship from the NHMRC.
In 2008 Alex established the Tumour Progression Laboratory in the Garvan Institute and in 2012 was appointed co-Head of the Breast Translational Oncology Program in the newly commissioned Kinghorn Cancer Centre. Alex is a Career Development Fellow of the NHMRC.
In the NewsLove Your Sister's Big Heart Project raises over $2 million for cancer research - May 11, 2017
Cancer Council NSW funding kickstarts research into colorectal cancer, breast cancer and osteosarcoma - Mar 02, 2017
Translational breast cancer research – translated to the public - Feb 14, 2017
NHMRC funding success for Garvan researchers - Nov 09, 2015
The switch that might tame the most aggressive of breast cancers - Mar 27, 2015
Laura Baker wins 2014 Castle Harlan Award - Nov 06, 2014
Aussie generosity still vital following medical future fund announcement - Jun 06, 2014
Garvan led team wins prestigious prostate cancer award - Mar 13, 2014
Overwhelming response for Ovarian Cancer Awareness Day Leader’s Lunch - Feb 28, 2014
Garvan performs well in NHMRC grants round - Oct 24, 2012
CINSW presents Premier’s Awards to two Garvan Researchers - Jul 15, 2011
Silencing a deadly conversation in breast cancer - Jun 02, 2011
A new way of reversing certain cancers - Sep 27, 2010
Targeting aggressive breast cancers by putting them to sleep - Mar 25, 2008
Awards and Honours
2012 - National Breast Cancer Foundation Fellowship
2011 - NSW Premier’s Award for Outstanding Research Fellow 2011
2009 - CINSW Early Career Fellowship
2007 - Sydney University Medal for Excellence in Medical Research
1995 - Molecular Biology, 1st Class Honours, University of New South Wales, Sydney - Australia
Australian Provisional Patent Application
Methods of treating breast cancer and reagents therefore
Australian Provisional Patent Application
Methods of treating neuroblastoma and reagents therefore
These two patent applications cover our discovery of novel therapeutic microRNA targets in cancer
Lin HM, Mahon KL, Spielman C, Gurney H, Mallesara G, Stockler MR, Bastick P, Briscoe K, Marx G, Swarbrick A, Horvath LG. Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer. Br J Cancer. 2017. [Epub ahead of print].
Sax MJ, Gasch C, Athota VR, Freeman R, Rasighaemi P, Westcott DE, Day CJ, Nikolic I, Elsworth B, Wei M, Rogers K, Swarbrick A, Mittal V, Pouliot N, Mellick AS. Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer. Oncotarget. 2016; 7: 85437-85449.
Beckers RK, Selinger C, Vilain R, Madore J, Wilmott JS, Harvey K, Holliday A, Cooper CL, Robbins E, Gillet D, Kennedy CW, Gluch L, Carmalt H, Mak C, Warrier S, Gee HE, Chan C, McLean A, Walker E, McNeil CM, Beith JM, Swarbrick A, Scolyer RA, O'Toole SA. PDl1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Pathology. 2016; 48 Suppl 1:S146-S147.
Baker LA, Holliday H, Swarbrick A. ID4 controls luminal lineage commitment in normal mammary epithelium and inhibits BRCA1 function in basal-like breast cancer. Endocr Relat Cancer. 2016; 23:R381-92.
Phua, Y., A. Nguyen, D. Roden, B. Elsworth, I. Nikolic, J. Yang, A. Mcfarland, R. Russell, W. Kaplan, R. Nair, E. Zotenko, S. Tan, S. Clark, H. Kouros-Mehr, and A. Swarbrick, MicroRNA profiling of the developing mammary gland identifies miR-184 as a candidate breast tumour suppressor gene. Breast Cancer Res. 2015; 17:83.
Junankar, S., G. Shay, J. Jurczyluk, N. Ali, J. Down, N. Pocock, A. Parker, A. Nguyen, S. Sun, B. Kashemirov, C.E. McKenna, P.I. Croucher, A. Swarbrick, K. Weilbaecher, T.G. Phan, and M.J. Rogers, Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer. Cancer Discovery, 2015. 5(1): p. 35-42.
Junankar, S., B. L., D.L. Roden, R. Nair, B. Elsworth, D. Gallego-Ortega, P. Lacaze, A. Cazet, I. Nikolic, W. Siang-Teo, J. Yang, A. McFarland, K. Harvey, M.J. Naylor, S.R. Lakhani, P.T. Simpson, A. Raghavendra, J. Saunus, J. Madore, W. Kaplan, C. Ormandy, E.K.A. Millar, S. O'Toole, K. Yun, and A. Swarbrick, ID4 controls mammary stem cells and marks breast cancers with a stem cell-like phenotype Nature Communications, 2015 6:6548.
Liu, P.Y., D. Erriquez, G.M. Marshall, A.E. Tee, P. Polly, M. Wong, B. Liu, J.L. Bell, X.D. Zhang, G. Milazzo, B.B. Cheung, A. Fox, A. Swarbrick, S. Huttelmaier, M. Kavallaris, G. Perini, J.S. Mattick, M.E. Dinger, and T. Liu, Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression. J Natl Cancer Inst, 2014. 106 (7).
Nair R, Roden DL, Teo WS, McFarland A, Junankar S, Ye S, Nguyen A, Yang J, Nikolic I, Hui M, Morey A, Shah J, Pfefferle AD, Usary J, Selinger C, Baker LA, Armstrong N, Cowley MJ, Naylor MJ, Ormandy CJ, Lakhani SR, Herschkowitz JI, Perou CM, Kaplan W, O'Toole SA, Swarbrick A. c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer. Oncogene. Oncogene, 2014. 33(30): p. 3992-4002
Plummer, P.N., R. Freeman, R.J. Taft, J. Vider, M. Sax, B.A. Umer, D. Gao, C. Johns, J.S. Mattick, S.D. Wilton, V. Ferro, N.A. McMillan, A. Swarbrick, V. Mittal, and A.S. Mellick, MicroRNAs Regulate Tumor Angiogenesis Modulated by Endothelial Progenitor Cells. Cancer Res, 2013;73(1): p. 341-352.
Hui, M., Cazet, A., Nair, R., Watkins, D.N., O'Toole, S.A. and Swarbrick, A. The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy. Breast Cancer Research. 2013; 15(2): p203.
Croucher, D.R., Hochgrafe, F., Zhang, L., Liu, L., Lyons, R.J., Rickwood, D., Tactacan, C.M., Browne, B.C., Ali, N., Chan, H., Shearer, R., Gallego-Ortega, D., Saunders, D.N., Swarbrick, A. and Daly, R.J. Involvement of Lyn and the atypical kinase SgK269/PEAK1 in a basal breast cancer signaling pathway. Cancer Research. 2013;73(6): p. 1969-1980.
Kalyuga, M., D. Gallego-Ortega, H.J. Lee, D.L. Roden, M.J. Cowley, C.E. Caldon, A. Stone, S.L. Allerdice, F. Valdes-Mora, R. Launchbury, A.L. Statham, N. Armstrong, M.C. Alles, A. Young, A. Egger, W. Au, C.L. Piggin, C.J. Evans, A. Ledger, T. Brummer, S.R. Oakes, W. Kaplan, J.M. Gee, R.I. Nicholson, R.L. Sutherland, A. Swarbrick, M.J. Naylor, S.J. Clark, J.S. Carroll, and C.J. Ormandy, ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer. PLoS Biol, 2012; 10(12): p. e1001461.
Croucher, D., F. Hochgräfe, L. Zhang, N. Ali, D. Rickwood, C. Tactacan, B. Browne, R. Lyons, L. Liu, A. Swarbrick, and R. Daly, A novel mitogenic signaling pathway in basal breast cancer involving Lyn and the atypical kinase SgK269. Cancer Research, 2012;
O'Toole, S.A., D.A. Machalek, R.F. Shearer, E.K. Millar, R. Nair, P. Schofield, D. McLeod, C.L. Cooper, C.M. McNeil, A. McFarland, A. Nguyen, C.J. Ormandy, M.R. Qiu, B. Rabinovich, L.G. Martelotto, D. Vu, G.E. Hannigan, E.A. Musgrove, D. Christ, R.L. Sutherland, D.N. Watkins, and A. Swarbrick, Hedgehog Overexpression Is Associated with Stromal Interactions and Predicts for Poor Outcome in Breast Cancer. Cancer Research, 2011; 71(11): p. 4002-4014.
Hochgrafe, F., L. Zhang, S.A. O'Toole, B.C. Browne, M. Pinese, A. Porta Cubas, G.M. Lehrbach, D.R. Croucher, D. Rickwood, A. Boulghourjian, R. Shearer, R. Nair, A. Swarbrick, D. Faratian, P. Mullen, D.J. Harrison, A.V. Biankin, R.L. Sutherland, M.J. Raftery, and R.J. Daly, Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Research, 2010; 70(22): p. 9391-401.
Mellick, A.S., P.N. Plummer, D.J. Nolan, D. Gao, K. Bambino, M. Hahn, R. Catena, V. Turner, K. McDonnell, R. Benezra, R. Brink, A. Swarbrick, and V. Mittal, Using the transcription factor inhibitor of DNA binding 1 to selectively target endothelial progenitor cells offers novel strategies to inhibit tumor angiogenesis and growth. Cancer Research, 2010; 70(18): p. 7273-82.
Swarbrick, A., S.L. Woods, A. Shaw, A. Balakrishnan, Y. Phua, A. Nguyen, Y. Chanthery, L. Lim, L.J. Ashton, R.L. Judson, N. Huskey, R. Blelloch, M. Haber, M.D. Norris, P. Lengyel, C.S. Hackett, T. Preiss, A. Chetcuti, C.S. Sullivan, E.G. Marcusson, W. Weiss, N. L'Etoile, and A. Goga, miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nature Medicine, 2010; 16(10): p. 1134-40.
Caldon, C.E., A. Swarbrick, C.S.L. Lee, R.L. Sutherland, and E.A. Musgrove, The Helix-Loop-Helix Protein Id1 Requires Cyclin D1 to Promote the Proliferation of Mammary Epithelial Cell Acini. Cancer Research, 2008; 68(8): p. 3026-3036
Swarbrick, A., E. Roy, T. Allen, and J.M. Bishop, Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response. PNAS, 2008; 105(14): p. 5402-5407